Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study

Abstract

To validate the correlation between ANXA3 expression and prognosis in breast cancer, a retrospective study encompassing 309 breast cancer patients was performed. The expression of ANXA3 was determined by the immunohistochemical examination of tissue sections by the Max Vision™ method. The ANXA3 levels in the patient samples were validated for the prognosis based on age, menopause status, tumor size, tumor node, metastasis stage, the number of lymphatic metastases, oncology grade, and molecular subtyping. An elevated expression of ANXA3 was detected in breast cancer samples, compared to adjacent tissue samples, and significant correlation depending on the number of lymphatic metastases (P = 0.001) and histological grade (P = 0.004) was observed. The number of lymphatic metastases and ANXA3 expression were identified as independent risk factors affecting the disease-free survival and overall survival. Significantly (P < 0.002) higher level of ANXA3 was detected in triple-negative breast cancer compared to other subtypes. There was no significant (P > 0.05) change in the expression of ANXA3 with respect to age, menopausal status, tumor size, and clinical stage. The findings implicate the expression of ANXA3 with the natural progression of breast cancer and associate it with increased lymphatic metastasis. The study validates the use of ANXA3 as a potential prognosis biomarker for breast cancer.

Annexin A3, a Calcium-Dependent Phospholipid-Binding Protein: Implication in Cancer

“…Specifically, ANXA3 expression in basal subtype of breast cancer (MDA-MB-231, HCC-70, HCC-1954) was found to be significantly higher than other subtypes (Kim et al, 2018). Other studies further confirmed that a significantly higher expression of ANXA3 was detect in TNBC cells in comparison to luminal A and B subtypes (Zhou et al, 2017b;Zhou et al, 2018). Furthermore, employing 2D-DIGE and iTRAQ approaches, Pendharkar et al demonstrated that ANXA3 upregulation is a marker for differentiating invasive ductal carcinoma with luminal B HER2 positive (LB) and HER2 enriched (HE) subtypes as well as their early and late stages (Pendharkar et al, 2016).…”

Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS

“…Further study confirmed that transfection of dendritic cells with ANXA3 activated autologous CD4 + T cells and CD8 + T cells to kill CD133 + hepatocellular carcinoma cells (28). Other previous studies have suggested that increased ANXA3 expression may be associated with the drug resistance of ovarian cancer (16,29), poor prognosis of breast cancer (29,30) and increased lymphatic metastasis (31).…”

Increased Expression of VANGL1 is Predictive of Lymph Node Metastasis in Colorectal Cancer: Results from a 20-Gene Expression Signature

“…Upregulation of the ANXA3 gene and its correlation with gastric tumor size, stage, and LNMs were detected by Wang et al [ 67 ] Moreover, these authors suggested that the overexpression of ANXA3 has a huge effect on gastric cancer malignancy, and it can be used as a novel prognostic biomarker and a suitable target for treatment [ 67 ]. Zhou et al reported that high expression levels of ANXA3 were significantly correlated with breast tumor LNMs and tumor grade, suggesting ANXA3 as a biomarker for breast cancer prognosis [ 68 ]. In our study, a significant overexpression of the ANXA3 gene in well-differentiated tumors compared with poorly differentiated tumors was instead observed.…”